Predicted Trait | |
Reported Trait | Prostate cancer |
Mapped Trait(s) | prostate carcinoma (EFO_0001663) |
Score Construction | |
PGS Name | PRCA_PRSCS |
Development Method | |
Name | PRS-CS |
Parameters | PRS-CS-auto, 1000G European sample (N = 503) as the external LD reference panel |
Variants | |
Original Genome Build | GRCh38 |
Number of Variants | 1,102,292 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000562 |
Citation (link to publication) | Youssef O et al. Lab Invest (2024) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 100% 140,254 individuals (100%) |
PGS Evaluation | European: 100% 1 Sample Sets |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST006085 Europe PMC: 29892016 |
140,254 individuals | European | NR |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM020696 | PSS011367| European Ancestry| 151,620 individuals |
PGP000562 | Youssef O et al. Lab Invest (2024) |
Reported Trait: Prostate cancer | OR: 2.13 [2.08, 2.17] | — | — | — | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS011367 | — | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |